Midtown Urology Associates Honored as Third Practice Nationwide To Have Two Physicians Designated as UroLift Center of Excellence

The UroLift System has fundamentally changed how we treat patients suffering bothersome BPH symptoms.

Midtown Urology Associates today announced that Drs. Michael Trotter and Brian Mazzarella of Midtown Urology Associates have been designated as UroLift® Centers of Excellence. The designation recognizes that Dr. Trotter and Dr. Mazzarella have demonstrated a commitment to exemplary care for men suffering from urinary tract symptoms due to benign prostatic hyperplasia (BPH) and have achieved a high level of training and experience with the UroLift System. Midtown Urology Associates is one of only three practices in the U.S. to have two physicians within the same practice earn this distinction.

“The UroLift System is a breakthrough minimally invasive treatment that takes less than an hour and offers multiple benefits for men with enlarged prostate – no cutting, heating, or removal of tissue, minimal downtime, no compromise of sexual function, and no need for continued medications,” said Dr. Trotter. “The UroLift System has fundamentally changed how we treat patients suffering bothersome BPH symptoms. We are proud to be national leaders in treating patients with this durable and effective treatment,” added Dr. Mazzarella.

Nearly 40 million men in the United States are affected by BPH. This condition occurs as the prostate gland that surrounds the male urethra becomes enlarged, exerting pressure on the urethra and restricting or blocking urine flow. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *